Pharmaceuticals firm FDC Announced Q1FY23 Result : The sale of branded formulations in India for Q1FY23 was Rs. 421.03 crores, with a growth of 8% on YoY and 52% on QoQ. Overall sales in the Indian market accounted for 85% of total consolidated sales for the quarter. As per secondary sales data by IQVIA for the quarter ended June 30, 2022, the Company delivered strong YoY growth of 21.6% compared to the Indian Pharmaceutical Market (IPM) growth of 17.2% YoY. This growth was mainly driven by Big brands like Zifi, Electral and Enerzal which witnessed a good volume growth. Electral has moved up to 34th in IPM in MAT Jun'22 as compared to 37th in the same period last year. Export Formulations Market: Formulation Sales in the Export market were Rs. 54.56 crores in Q1FY23, up by 26.5% over YoY and up by 15% over QoQ and accounted for 11% of total consolidated sales. The main contributor is the USA market, accounting for 52% of total Export Formulations Sales. ANDA is filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%. API Sales in the Export market were Rs. 17.37 crores in QIFY23, up by 25% over YoY and up by 21% over QoQ and accounted for 4% of total consolidated sales. Result PDF
Pharmaceuticals compay FDC declares Q4FY22 result: Q4FY22 revenue at Rs. 278.38 Crore, up 18% YoY FY22 revenue at Rs. 1,304.44 Crore, up 31% YoY As per secondary sales data by IQVIA for the period MAT Mar'22, the Company delivered a strong YoY growth of 19% compared to Indian Pharmaceutical Market (IPM) growth of 18% YoY. This growth was mainly driven by Big brands like Ziti, Electral, Enerzal and Zathrin which witnessed a good volume growth. FDC has moved one rank up from 23rd in MAT Mar'21 to 22nd in MAT Mar'22 in IPM. On MAT Mar'22, Ziti's rank has moved to 39th largest brand in IPM from 53rd in the same period last year while Electral has moved up to 40th in IPM from 43rd in the same period last year. Export Formulations Market: Q4FY22 revenue at Rs. 47.28 Crores, down 17% YoY FY22 revenue at Rs. 163.27 Crores, down 39% YoY We have received registration for Electral in several countries, this is in line with our efforts of making Electral a global brand across territories. Q4FY22 revenue at Rs.14.35 Crores, down 24% YoY FY22 revenue at Rs. 55.95 Crores, down 8% YoY Result PDF
Pharmaceuticals company FDC announced Q3FY22 results: Q3FY22 revenue at Rs. 288.42 Crore, up 15% YoY 9MFY22 revenue at Rs.1,026.06 Crore, up 35% YoY Overall sales in India markets accounted for 85% of total consolidated sales for the quarter. Commenting on the results; "We saw good growth in our Domestic business, which is a big pie of our overall business. This was driven by robust demand across our established therapies and brands leading to 35 % revenue growth. Our USA business portfolio saw some price erosion and lower demand for current portfolio laid by re-entry of competitors, still our partner has been successful in maintaining good portion of market share." Result PDF